

Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

Laith J. Abu-Raddad,^{1,2,3,4*} Hiam Chemaitelly,^{1,2} Houssein H. Ayoub,⁵ Hadi M. Yassine,^{6,7} Fatiha M. Benslimane,^{6,7} Hebah A. Al Khatib,^{6,7} Patrick Tang,⁸ Mohammad R. Hasan,⁸ Peter Coyle,^{6,9,10} Sawsan AlMukdad,^{1,2} Zaina Al Kanaani,⁹ Einas Al Kuwari,⁹ Andrew Jeremijenko,⁹ Anvar Hassan Kaleeckal,⁹ Ali Nizar Latif,⁹ Riyazuddin Mohammad Shaik,⁹ Hanan F. Abdul Rahim,⁴ Gheyath K. Nasrallah,^{6,7} Mohamed Ghaith Al Kuwari,¹¹ Adeel A. Butt,^{3,9} Hamad Eid Al Romaihi,¹² Mohamed H. Al-Thani,¹² Abdullatif Al Khal,⁹ and Roberto Bertollini,¹²

¹*Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar*

²*World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar*

³*Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA*

⁴*Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar*

⁵*Department of Mathematics, Statistics, and Physics, Qatar University, Doha, Qatar*

⁶*Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar*

⁷*Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar*

⁸*Department of Pathology, Sidra Medicine, Doha, Qatar*

⁹*Hamad Medical Corporation, Doha, Qatar*

¹⁰*Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom*

¹¹*Primary Health Care Corporation, Doha, Qatar*

¹²*Ministry of Public Health, Doha, Qatar*

Word count: Abstract: 90 words, Main Text: 1,248 words.

Number of tables: 1.

Number of figures: 1.

Running head: Severity and fatality of the SARS-CoV-2 Beta variant.

Keywords: SARS-CoV-2; variant; infection; case-control; severe disease; epidemiology.

* Address reprints requests or correspondence to Professor Laith J. Abu-Raddad, Infectious Disease Epidemiology Group, World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar. Telephone: +(974) 4492-8321. Fax: +(974) 4492-8333. E-mail: lja2002@qatar-med.cornell.edu.

Abstract

Severity (acute-care hospitalization), criticality (ICU hospitalization), and fatality of SARS-CoV-2 Beta (B.1.351) variant was investigated through case-control studies applied to complete national cohorts of infection, disease, and death cases in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher. Findings highlight risks to healthcare systems, particularly to intensive care facilities and resources, with increased circulation of Beta.

Introduction

Commencing in mid-January, 2021, Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Alpha (B.1.1.7) variant wave that peaked in the first week of March [1-5], but was immediately followed by a Beta (B.1.351) variant wave that peaked in the first week of April [1-5]. This created a unique epidemiologic situation that allowed comparative assessment of the severity, criticality, and fatality of these two variants.

Methods

We investigated severity (acute-care hospitalization) [6], criticality (ICU hospitalization) [6], and fatality [7] of both variants through eight case-control studies applied to the complete national cohorts of SARS-CoV-2 infections, Coronavirus Disease 2019 (COVID-19) disease cases, and COVID-19 deaths in Qatar, a country with diverse demographics where 89% of the population comprises expatriates from over 150 countries [8]. Data on polymerase chain reaction (PCR) testing and clinical characteristics were extracted from the national, federated COVID-19 databases that have captured all SARS-CoV-2-related data since the start of the epidemic. These databases were retrieved from the integrated nationwide digital-health information platform (universal healthcare system), and include all records of PCR testing, antibody testing, vaccinations, COVID-19 hospitalizations, infection severity classification, and COVID-19 deaths. Databases are complete at the national level with no missing information.

Records of PCR testing and clinical data for hospitalized COVID-19 patients were examined. Details of the laboratory methods for PCR testing are found in Supplementary Text 1. Each person that had a positive PCR test result and hospital admission was subject to an infection severity assessment every three days until discharge or death. Individuals who progressed to COVID-19 disease between the time of the positive PCR test result and the end of the study were

classified based on their worst outcome, starting with death [7], followed by critical disease [6], and then severe disease [6].

Cases in the case-control studies were persons who progressed to COVID-19 severe disease, critical disease, or death. Controls were persons with asymptomatic or mild SARS-CoV-2 infections. Cases and controls were matched at a ratio of 1:3 by 10-year age group, sex, and bi-weekly interval of the PCR diagnosis date. Every case in Qatar that met the inclusion criteria and that could be matched to a control was included in the study. Classification of case severity, criticality, and fatality followed the World Health Organization guidelines [6, 7], and assessments were made by trained medical personnel through individual chart reviews. Details of the COVID-19 severity, criticality, and fatality classification are found in Supplementary Text 2.

From January 18 until February 15, 2021, the Alpha variant wave expanded rapidly and weekly rounds of viral genome sequencing [1-4] of randomly collected samples confirmed the presence of this and other originally circulating “wild-type” variants, but documented only limited presence of the Beta variant and no other variants of concern [1-4]. This allowed a comparative assessment for the Alpha variant versus wild-type variants during this specific timeframe (Supplementary Text 3). From March 8 through May 31, 2021, the Beta variant wave expanded rapidly and viral genome sequencing [1-4] and multiplex quantitative reverse-transcription PCR (RT-qPCR) variant screening [1-5] indicated dominance of the Beta and Alpha variants, with limited presence of other variants [1-5]. This enabled comparisons between the Beta versus Alpha variants during this specific timeframe (Supplementary Text 3). The Delta [9] (B.1.617.2) variant has been introduced only recently in Qatar, and it remains at low incidence as of July 11, 2021 [3-5]. Further details on the classification of infections by variant type are found in Supplementary Text 3.

Descriptive statistics (frequency distributions and measures of central tendency) were used to characterize the study samples. Two-sided p-value of <0.05 was considered statistically significant. The odds ratio and its associated 95% confidence interval (CI) were calculated using the exact method. Confidence intervals were not adjusted for multiplicity. Interactions were not investigated. Two sensitivity analyses were conducted by first adjusting for age, and second by adjusting for age and sex, in logistic regression analyses. Statistical analyses were conducted in STATA/SE version 17.0.

The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with waiver of informed consent. Reporting of the study followed the STROBE guidelines (Supplementary Table 1).

Results

Demographic characteristics of the samples for each disease outcome in assessing the severity, criticality, and fatality of the Alpha variant compared to the wild-type variants are presented in Supplementary Table 2. Compared to wild-type variants, the odds of progressing to severe disease were 1.48-fold (95% CI: 1.18-1.84) higher for the Alpha variant (Table 1). The odds of progressing to critical disease were 1.58-fold (95% CI: 0.79-3.10) higher, but did not reach statistical significance. There were too few COVID-19 deaths to assess the fatality of the Alpha variant.

Demographic characteristics of the samples for each disease outcome in assessing the severity, criticality, and fatality of the Beta variant compared to the Alpha variant are presented in Supplementary Table 3. Compared to the Alpha variant, the odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for the Beta variant (Table 1). The odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. The odds of COVID-

19 death were 1.57-fold (95% CI: 1.03-2.43) higher. Sensitivity analyses confirmed the above results (Supplementary Table 4).

Discussion

The Alpha variant presented a 48% higher risk of severe disease than wild-type variants in the population of Qatar, affirming its greater gravity [10, 11] (odds ratio approximates risk ratio for rate outcomes). Infection with the Beta variant was associated with even greater risks of severe and critical disease and COVID-19 death, affirming earlier observational analyses suggesting its high gravity [11, 12]. Compared to the Alpha variant, infections with the Beta variant posed a 24% higher risk of severe disease, 49% higher risk of critical disease, and 57% higher risk of COVID-19 death.

These results explain the changing pattern of hospitalizations and deaths seen during the Beta wave compared to the Alpha wave (Figure 1). Acute-care admissions doubled during the Beta wave, but ICU admissions and deaths quadrupled, with the disproportionately greater effect of this variant on critical disease and COVID-19 death.

Limitations include the smaller sample sizes of critical disease and COVID-19 deaths in the Alpha variant analysis (Supplementary Table 2) compared to the Beta variant analysis (Supplementary Table 3), as COVID-19 criticality and fatality have been low in Qatar's predominantly young and working-age population [8, 13], leading to statistically non-significant results and wider 95% confidence intervals. Data on co-morbid conditions were not available to study investigators; hence, they could not be factored explicitly in our analysis. Nevertheless, matching and adjusting for age in analysis may have served as a proxy, given that co-morbidities are associated with old age. Furthermore, with the young population structure [8], we anticipate that only a small proportion of the study population may have had serious co-morbid conditions.

However, our findings may not be entirely generalizable to other settings, where elderly people constitute a sizable proportion of the population. Imperfect assay sensitivity and specificity of PCR testing may have affected infection ascertainment. However, all PCR testing was performed with extensively used, investigated, and validated commercial platforms having essentially 100% sensitivity and specificity (Supplementary Text 1). Unlike blinded, randomized clinical trials, the investigated observational cohorts were neither blinded nor randomized.

In conclusion, the Alpha variant is associated with 48% higher risk of severe disease than wild-type variants. In turn, the Beta variant is associated with 24% higher risk of severe disease than the Alpha variant, and strikingly, even higher risk of critical disease (49%) and COVID-19 death (57%). These findings highlight risks to healthcare systems, particularly intensive care facilities and resources, in the event of a globally increased circulation of the Beta variant.

Funding

The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health and Hamad Medical Corporation. The authors are also grateful for the Qatar Genome Programme for supporting the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.

Acknowledgements

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, and the Qatar Biobank for their diligent efforts and contributions to make this study possible.

Author contributions

LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

Competing interests

Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests.

Data availability

The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (<https://www.moph.gov.qa/english/Pages/default.aspx>). Aggregate data are available within the manuscript and its Supplementary information.

References

1. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for Covid-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* **2021**.
2. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* **2021**.
3. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. <https://www.gisaid.org/phylogenetics/global/nextstrain/>. Available at: <https://www.gisaid.org/phylogenetics/global/nextstrain/>.
4. Benslimane FM, Al Khatib HA, Al-Jamal O, et al. One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar. *medRxiv* **2021**: 2021.05.19.21257433.
5. Hasan MR, Kalikiri MKR, Mirza F, et al. Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. *medRxiv* **2021**: 2021.07.18.21260718.
6. World Health Organization. COVID-19 clinical management: living guidance. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>. Accessed on: May 15 2021. **2021**.
7. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1. Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 31, 2021. **2021**.
8. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Scientific Reports* **2021**; 11(1): 6233.
9. World Health Organization. Tracking SARS-CoV-2 variants. Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>. Accessed on: June 5, 2021. **2021**.
10. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* **2021**; 372: n579.
11. Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. *Euro Surveill* **2021**; 26(16).
12. Jassat W, Mudara C, Ozougwu L, et al. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. *Lancet Glob Health* **2021**.
13. Seedat S, Chemaitelly H, Ayoub H, et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates. *medRxiv* 2020112920240416 **2020**.

Table 1. Infection severity, criticality, and fatality of the Alpha and Beta variants in the population of Qatar.

Groups	Infection severity [‡]	Assessment of severity, criticality, and fatality of the Alpha variant compared to the wild-type variants circulating between January 18-February 15, 2021 [*]			Assessment of severity, criticality, and fatality of the Beta variant compared to the Alpha variant between March 8-May 31, 2021 [†]		
		Exposed	Not exposed	Odds ratio (95% CI)	Exposed	Not exposed	Odds ratio (95% CI)
		Alpha variant	Wild-type variants		Beta variant	Alpha variant	
Cases ^{**}	Severe disease	188	279	1.48 (1.18-1.84)	2,036	483	1.24 (1.11-1.39)
Controls ^{**}	Asymptomatic or mild infection	431	944		5,806	1,707	
Cases ^{**}	Critical disease	21	37	1.58 (0.79-3.10)	382	81	1.49 (1.13-1.97)
Controls ^{**}	Asymptomatic or mild infection	49	125		1,056	333	
Cases ^{**}	Severe or critical disease	209	316	1.45 (1.18-1.79)	2,418	564	1.28 (1.15-1.42)
Controls ^{**}	Asymptomatic or mild infection	480	1,054		6,764	2,019	
Cases ^{**}	COVID-19 death	2	9	0.83 (0.07-5.58)	142	37	1.57 (1.03-2.43)
Controls ^{**}	Asymptomatic or mild infection	7	26		381	156	

Abbreviations: PCR, polymerase chain reaction.


^{*}From January 18-February 15, 2021, the Alpha variant and other wild-type variants dominated incidence with limited presence of the Beta variant[1-4].

[†]From March 8-May 31, 2021, the Beta and Alpha variants dominated incidence with limited presence for other variants[1-5].

[‡]Severe disease, critical disease, and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity[6] and COVID-19-related death[7].

^{**}Cases and controls were matched on a ratio of one-to-three by 10-year age group, sex, and bi-weekly interval of the PCR diagnosis date.

Figure 1. Number of A) daily new COVID-19 acute-care hospital admissions, B) daily new COVID-19 ICU hospital admissions, and C) COVID-19 deaths in Qatar.



Supplementary Material

Table of Contents

Supplementary Text 1. Laboratory methods	2
Supplementary Text 2. COVID-19 severity, criticality, and fatality classification	3
Supplementary Text 3. Classification of infections by variant type	4
Supplementary Table 1. STROBE checklist for case-control studies	5
Supplementary Table 2. Assessment of the severity, criticality, and fatality of the Alpha variant compared to wild-type variants. Demographic characteristics of A) patients experiencing COVID-19 severe disease and controls (asymptomatic or mild SARS-CoV-2 infection), B) patients experiencing COVID-19 critical disease and controls (asymptomatic or mild SARS-CoV-2 infection), and C) cases resulting in COVID-19 death and controls (non-fatal infection)	7
Supplementary Table 3. Assessment of the severity, criticality, and fatality of the Beta variant compared to the Alpha variant. Demographic characteristics of A) patients experiencing COVID-19 severe disease and controls (asymptomatic or mild SARS-CoV-2 infection), B) patients experiencing COVID-19 critical disease and controls (asymptomatic or mild SARS-CoV-2 infection), and C) cases resulting in COVID-19 death and controls (non-fatal infection)	8
Supplementary Table 4. Sensitivity analyses for COVID-19 severity, criticality, and fatality in Qatar after A) adjusting for age in logistic regression analysis, and B) adjusting for age and sex in logistic regression analysis	9
References	10

Supplementary Text 1. Laboratory methods.

Nasopharyngeal and/or oropharyngeal swabs (Huachenyang Technology, China) were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on a QIASymphony platform (QIAGEN, USA) and tested with real-time reverse-transcription PCR (RT-qPCR) using TaqPath™ COVID-19 Combo Kits (100% sensitivity and specificity [1]; Thermo Fisher Scientific, USA) on an ABI 7500 FAST (ThermoFisher, USA); extracted using a custom protocol [2] on a Hamilton Microlab STAR (Hamilton, USA) and tested using AccuPower SARS-CoV-2 Real-Time RT-PCR Kits (100% sensitivity and specificity [3]; Bioneer, Korea) on an ABI 7500 FAST; or loaded directly into a Roche cobas® 6800 system and assayed with a cobas® SARS-CoV-2 Test (95% sensitivity, 100% specificity [4]; Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab regions. The second targets the viral RdRp and E-gene regions, and the third targets the ORF1ab and E-gene regions.

All PCR tests were conducted at the Hamad Medical Corporation Central Laboratory or Sidra Medicine Laboratory, following standardized protocols.

Supplementary Text 2. COVID-19 severity, criticality, and fatality classification.

Severe COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with “oxygen saturation of $<90\%$ on room air, and/or respiratory rate of >30 breaths/minute in adults and children >5 years old (or ≥ 60 breaths/minute in children <2 months old or ≥ 50 breaths/minute in children 2–11 months old or ≥ 40 breaths/minute in children 1–5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)” [5]. Detailed WHO criteria for classifying SARS-CoV-2 infection severity can be found in the WHO technical report [5].

Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with “acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy” [5]. Detailed WHO criteria for classifying SARS-CoV-2 infection criticality can be found in the WHO technical report [5].

COVID-19 death was defined per WHO classification as “a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g. cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19”. Detailed WHO criteria for classifying COVID-19 death can be found in the WHO technical report [6].

Supplementary Text 3. Classification of infections by variant type.

Classification of infections by variant type was informed by weekly rounds of viral genome sequencing and multiplex, real-time reverse-transcription PCR (RT-qPCR) variant screening [7] of randomly collected clinical samples [8-12], as well as by results of deep sequencing of wastewater samples [10]. Based on existing evidence [13-15] and confirmation with viral genome sequencing [16], an Alpha case was defined as an S-gene “target failure” using the TaqPath COVID-19 Combo Kits (Thermo Fisher Scientific, USA [1]; >85% of PCR testing in Qatar) applying the criterion of a PCR cycle threshold (Ct) value ≤ 30 for both the N and ORF1ab genes, and a negative outcome for the S gene [15].

From January 18 until February 15, 2021, the weekly rounds of viral genome sequencing [8-11] identified presence of the Alpha variant and other originally circulating “wild-type” variants, but documented only limited presence of the Beta variant and no presence of other variants of concern [8-11]. Meanwhile, with essentially only Beta and Alpha cases identified from March 8, 2021 until the end of study (May 31, 2021) in the viral genome sequencing and multiplex RT-qPCR variant screening [8-12], a Beta case was proxied as the complement of Alpha criteria, that is, any infection with a Ct value ≤ 30 for the N, ORF1ab, and S genes. The Delta [17] (B.1.617.2) variant has been introduced only recently in Qatar, and it remains at low incidence as of July 11, 2021 [10-12]. There is no evidence that any other variant of concern is or has been responsible for appreciable community transmission in Qatar [10, 11].

Supplementary Table 1. STROBE checklist for case-control studies.

	Item No	Recommendation	Main text page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3-4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3-4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	3-4 & Supp. Text 2
		(b) For matched studies, give matching criteria and the number of controls per case	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3-5 & Supp. Texts 1-3
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3, 5 & Supp. Texts 1-3
Bias	9	Describe any efforts to address potential sources of bias	4-5
Study size	10	Explain how the study size was arrived at	3-4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Table 1 & Supp. Tables 2-4 & Supp. Text 3
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	4-5
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA, see p. 3
		(d) If applicable, explain how matching of cases and controls was addressed	4
		(e) Describe any sensitivity analyses	5
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	3-5, Table 1 & Supp. Tables 2-3
		(b) Give reasons for non-participation at each stage	NA, see p. 3
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5, Supp. Tables 2-3
		(b) Indicate number of participants with missing data for each variable of interest	NA, see p. 3
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	5-6, Table 1 & Supp. Table 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5-6 & Table 1
		(b) Report category boundaries when continuous variables were categorized	Table 1 & Supp. Tables 2-4

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6 & Supp. Table 4
Discussion			
Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	6-7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	7
Generalisability	21	Discuss the generalisability (external validity) of the study results	7
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	8

NA, not applicable; Supp, supplementary

Supplementary Table 2. Assessment of the severity, criticality, and fatality of the Alpha variant compared to wild-type variants. Demographic characteristics of A) patients experiencing COVID-19 severe disease and controls (asymptomatic or mild SARS-CoV-2 infection), B) patients experiencing COVID-19 critical disease and controls (asymptomatic or mild SARS-CoV-2 infection), and C) cases resulting in COVID-19 death and controls (non-fatal infection).

Sample type	A) Infection severity			B) Infection criticality			C) Infection fatality		
Characteristics	Cases* (Severe disease)	Controls* (Asymptomatic or mild infection)	p-value	Cases* (Critical disease)	Controls* (Asymptomatic or mild infection)	p-value	Cases* (COVID-19 death)	Controls* (Asymptomatic or mild infection)	p-value
Median age (IQR) — years	46 (39-56)	45 (38-54)	0.040	51 (42-60)	51 (42-61)	0.816	65 (52-81)	63 (55-70)	0.459
Age group — no. (%)									
<30 years	15 (3.2)	45 (3.3)	0.689	1 (1.7)	3 (1.7)	1.000	--	--	1.000
30-39 years	117 (25.1)	351 (25.5)		6 (10.3)	18 (10.3)		--	--	
40-49 years	158 (33.8)	474 (34.5)		19 (32.8)	57 (32.8)		2 (18.2)	6 (18.2)	
50-59 years	95 (20.3)	285 (20.7)		17 (29.3)	51 (29.3)		1 (9.1)	3 (9.1)	
60-69 years	58 (12.4)	174 (12.7)		9 (15.5)	27 (15.5)		5 (45.5)	15 (45.5)	
70+ years	24 (5.1)	46 (3.4)		6 (10.3)	18 (10.3)		3 (27.3)	9 (27.3)	
Sex									
Male	355 (76.0)	1,053 (76.6)	0.804	45 (77.6)	135 (77.6)	1.000	11 (100.0)	33 (100.0)	--
Female	112 (24.0)	322 (23.4)		13 (22.4)	39 (22.4)		--	--	
Nationality[†]									
Bangladeshi	15 (3.2)	72 (5.8)		2 (3.5)	6 (3.5)		1 (9.1)	0 (0.0)	
Egyptian	50 (10.7)	103 (7.5)		5 (8.6)	8 (4.6)		--	--	
Filipino	64 (13.7)	121 (8.8)		10 (17.2)	14 (8.1)		0 (0.0)	2 (6.1)	
Indian	110 (23.6)	434 (31.6)	<0.001	19 (32.8)	61 (35.1)	0.446	5 (45.5)	8 (24.2)	0.187
Nepalese	22 (4.7)	69 (5.0)		0 (0.0)	6 (3.5)		0 (0.0)	2 (6.1)	
Pakistani	26 (5.6)	79 (5.8)		4 (6.9)	13 (7.5)		1 (9.1)	4 (12.1)	
Qatari	46 (9.9)	111 (8.1)		5 (8.6)	18 (10.3)		1 (9.1)	4 (12.1)	
Sri Lankan	8 (1.7)	43 (3.1)		0 (0.0)	4 (2.3)		--	--	
Sudanese	12 (2.6)	54 (3.9)		2 (3.5)	4 (2.3)		2 (18.2)	5 (15.2)	
Other nationalities [‡]	114 (24.4)	289 (21.0)		11 (19.0)	40 (23.0)		1 (9.1)	8 (24.2)	

*Cases and controls were matched on a ratio of one-to-three by 10-year age group, sex, and bi-weekly interval of the PCR diagnosis date. Severe disease, critical disease, and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity [5] and COVID-19-related death [6].

[†]Nationalities were chosen to represent the most populous groups in the population of Qatar.

[‡]These comprise 32 other nationalities among cases and 49 other nationalities in Qatar among controls in sample A, 8 other nationalities among cases and 20 other nationalities among controls in sample B, 1 other nationality (Iranian) among cases and 9 other nationalities among controls in sample C.

Supplementary Table 3. Assessment of the severity, criticality, and fatality of the Beta variant compared to the Alpha variant. Demographic characteristics of A) patients experiencing COVID-19 severe disease and controls (asymptomatic or mild SARS-CoV-2 infection), B) patients experiencing COVID-19 critical disease and controls (asymptomatic or mild SARS-CoV-2 infection), and C) cases resulting in COVID-19 death and controls (non-fatal infection).

Sample type	A) Infection severity			B) Infection criticality			C) Infection fatality		
	Cases* (Severe disease)	Controls* (Asymptomatic or mild infection)	p-value	Cases* (Critical disease)	Controls* (Asymptomatic or mild infection)	p-value	Cases* (COVID-19 death)	Controls* (Asymptomatic or mild infection)	p-value
Median age (IQR) — years	45 (38-53)	44 (38-52)	0.002	51 (44-60)	51 (42-60)	0.253	57 (49-70)	56 (47-70)	0.140
Age group — no. (%)									
<30 years	101 (4.0)	303 (4.0)	0.902	4 (0.9)	12 (0.9)	1.000	1 (0.6)	3 (0.6)	1.000
30-39 years	628 (24.9)	1,884 (25.1)		63 (13.6)	189 (13.6)		9 (5.0)	27 (5.0)	
40-49 years	898 (35.7)	2,694 (35.9)		137 (29.6)	411 (29.6)		42 (23.5)	126 (23.5)	
50-59 years	591 (23.5)	1,773 (23.6)		141 (30.5)	423 (30.5)		50 (27.9)	150 (27.9)	
60-69 years	193 (7.7)	579 (7.7)		66 (14.3)	198 (14.3)		31 (17.3)	93 (17.3)	
70+ years	108 (4.3)	280 (3.7)		52 (11.2)	156 (11.2)		46 (25.7)	138 (25.7)	
Sex									
Male	1,962 (77.9)	5,859 (78.0)	0.919	345 (74.5)	1,035 (74.5)	1.000	130 (72.6)	390 (72.6)	1.000
Female	557 (22.1)	1,654 (22.0)		118 (25.5)	354 (25.5)		49 (27.4)	147 (27.4)	
Nationality[†]									
Bangladeshi	223 (8.9)	568 (7.6)	<0.001	36 (7.8)	88 (6.3)	0.011	12 (6.7)	31 (5.8)	0.249
Egyptian	167 (6.6)	368 (4.9)		22 (4.8)	72 (5.2)		5 (2.8)	21 (3.9)	
Filipino	422 (16.8)	819 (10.9)		78 (16.9)	159 (11.5)		23 (12.9)	42 (7.8)	
Indian	570 (22.6)	2,516 (33.5)		113 (24.4)	415 (29.9)		45 (25.1)	133 (24.8)	
Nepalese	223 (8.9)	577 (7.7)		20 (4.3)	81 (5.8)		3 (1.7)	28 (5.2)	
Pakistani	111 (4.4)	333 (4.4)		24 (5.2)	78 (5.6)		12 (6.7)	36 (6.7)	
Qatari	213 (8.5)	645 (8.6)		66 (14.3)	144 (10.4)		35 (19.6)	86 (16.0)	
Sri Lankan	82 (3.3)	312 (4.2)		23 (5.0)	61 (4.4)		8 (4.5)	20 (3.7)	
Sudanese	62 (2.5)	204 (2.7)		11 (2.4)	41 (3.0)		5 (2.8)	20 (3.7)	
Other nationalities [‡]	446 (17.7)	1,171 (15.6)		70 (15.2)	250 (18.0)		31 (17.3)	120 (22.4)	

*Cases and controls were matched on a ratio of one-to-three by 10-year age group, sex, and bi-weekly interval of the PCR diagnosis date. Severe disease, critical disease, and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity [5] and COVID-19-related death [6].

[†]Nationalities were chosen to represent the most populous groups in the population of Qatar.

[‡]These comprise 51 other nationalities among cases and 77 other nationalities in Qatar among controls in sample A, 19 other nationalities among cases and 44 other nationalities in Qatar among controls in sample B, and 13 other nationalities among cases and 29 other nationalities in Qatar among controls in sample C.

Supplementary Table 4. Sensitivity analyses for COVID-19 severity, criticality, and fatality in Qatar after A) adjusting for age in logistic regression analysis, and B) adjusting for age and sex in logistic regression analysis.

Groups	Infection severity [‡]	Assessment of severity, criticality, and fatality of the Alpha variant compared to the wild-type variants circulating between January 18-February 15, 2021 [*]			Assessment of severity, criticality, and fatality of the Beta variant compared to the Alpha variant between March 8-May 31, 2021 [†]		
		Exposed	Not exposed	Odds ratio (95% CI)	Exposed	Not exposed	Odds ratio (95% CI)
		Alpha variant	Wild-type variants		Beta variant	Alpha variant	
A) Adjusting for age in logistic regression analysis^{**}							
Cases ^{††}	Severe disease	188	279	1.49 (1.19-1.85)	2,036	483	1.24 (1.11-1.39)
Controls ^{††}	Asymptomatic or mild infection	431	944		5,806	1,707	
Cases ^{††}	Critical disease	21	37	1.58 (0.84-2.99)	382	81	1.49 (1.14-1.95)
Controls ^{††}	Asymptomatic or mild infection	49	125		1,056	333	
Cases ^{††}	Severe or critical disease	209	316	1.47 (1.169-1.80)	2,418	564	1.28 (1.15-1.42)
Controls ^{††}	Asymptomatic or mild infection	480	1,054		6,764	2,019	
Cases ^{††}	COVID-19 death	2	9	0.82 (0.14-4.90)	142	37	1.57 (1.05-2.36)
Controls ^{††}	Asymptomatic or mild infection	7	26		381	156	
B) Adjusting for age and sex in logistic regression analysis^{**}							
Cases ^{††}	Severe disease	188	279	1.49 (1.19-1.85)	2,036	483	1.25 (1.11-1.40)
Controls ^{††}	Asymptomatic or mild infection	431	944		5,806	1,707	
Cases ^{††}	Critical disease	21	37	1.59 (0.84-3.01)	382	81	1.50 (1.14-1.97)
Controls ^{††}	Asymptomatic or mild infection	49	125		1,056	333	
Cases ^{††}	Severe or critical disease	209	316	1.46 (1.19-1.80)	2,418	564	1.29 (1.16-1.43)
Controls ^{††}	Asymptomatic or mild infection	480	1,054		6,764	2,019	
Cases ^{††}	COVID-19 death	2	9	0.82 (0.14-4.90)	142	37	1.58 (1.05-2.38)
Controls ^{††}	Asymptomatic or mild infection	7	26		381	156	

Abbreviations: PCR, polymerase chain reaction.

^{*}From January 18-February 15, 2021, the Alpha variant and other wild-type variants dominated incidence with limited presence of the Beta variant [8-11].

[†]From March 8-May 31, 2021, the Beta and Alpha variants dominated incidence with limited presence for other variants [8-12].

[‡]Severe disease, critical disease, and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity[5] and COVID-19-related death[6].

^{**}Age was included as a dichotomous variable (<50 years vs. ≥50 years) in the logistic regression analyses.

^{††}Cases and controls were matched on a ratio of one-to-three by 10-year age group, sex, and bi-weekly interval of the PCR diagnosis date.

References

1. Thermo Fisher Scientific. TaqPath™ COVID-19 CE-IVD RT-PCR Kit instructions for use. Available from: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0019215_TaqPathCOVID-19_CE-IVD_RT-PCR%20Kit_IFU.pdf. Accessed on December 02, 2020. **2020**.
2. Kalikiri MKR, Hasan MR, Mirza F, Xaba T, Tang P, Lorenz S. High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads. medRxiv **2020**: 2020.04.08.20055731.
3. Kubina R, Dziedzic A. Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics. Diagnostics (Basel) **2020**; 10(6).
4. US Food and Drug Administration. Cobas® SARS-CoV-2: Qualitative assay for use on the cobas® 6800/8800 Systems. Available from: <https://www.fda.gov/media/136049/download>. Accessed on: December 02, 2020. **2020**.
5. World Health Organization. COVID-19 clinical management: living guidance. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>. Accessed on: May 15 2021. **2021**.
6. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1. Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 31, 2021. **2021**.
7. Vogels C, Fauver J, Grubaugh N. Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. dx.doi.org/10.17504/protocols.io.br9vm966. Available at: <https://www.protocols.io/view/multiplexed-rt-qpcr-to-screen-for-sars-cov-2-b-1-1-br9vm966>. Accessed June 6, 2021.
8. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for Covid-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med **2021**.
9. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med **2021**.
10. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. <https://www.gisaid.org/phylogenetics/global/nextstrain/>. Available at: <https://www.gisaid.org/phylogenetics/global/nextstrain/>.
11. Benslimane FM, Al Khatib HA, Al-Jamal O, et al. One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar. medRxiv **2021**: 2021.05.19.21257433.
12. Hasan MR, Kalikiri MKR, Mirza F, et al. Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. medRxiv **2021**: 2021.07.18.21260718.
13. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. Available

- from: <https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf>. Accessed on: February 10, 2021.
14. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(3): 95-9.
 15. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* **2021**; 372: n579.
 16. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Epidemiologic characterization of introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and its reinfections in a national population. Under review **2021**.
 17. World Health Organization. Tracking SARS-CoV-2 variants. Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>. Accessed on: June 5, 2021. **2021**.